XENSE
Private Company
Funding information not available
Overview
XENSE is an early-stage, private AI/ML diagnostics company targeting the neurology and psychiatry markets with its uTomo platform for advanced X-ray imaging. The company is in a pre-revenue, pre-clinical development stage and is currently raising capital from accredited investors via platforms like Wefunder and StartEngine. Leadership includes founder Ying Zhao as CEO/CTO and Dr. Sean Lavine heading Medical Affairs, indicating a blend of technical and clinical expertise. The primary near-term goals appear to be technology development, validation, and securing initial funding.
Technology Platform
uTomo platform for next-generation X-ray imaging and AI, described as 'Meta CT,' aiming to generate advanced diagnostic data and digital biomarkers from X-ray sources.
Opportunities
Risk Factors
Competitive Landscape
The AI-medical imaging field is intensely competitive, with numerous companies developing algorithms for radiology. XENSE must differentiate its focus on neurology/psychiatry from X-ray data and demonstrate clear clinical utility against established imaging modalities like MRI and CT, as well as other digital biomarker approaches.